Candel Therapeutics (CADL) Income from Continuing Operations: 2020-2023
Historic Income from Continuing Operations for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$5.4 million.
- Candel Therapeutics' Income from Continuing Operations rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' Income from Continuing Operations is -$5.4 million, which was up 40.34% from -$9.0 million recorded in Q3 2023.
- Candel Therapeutics' Income from Continuing Operations' 5-year high stood at -$2.4 million during Q2 2020, with a 5-year trough of -$9.8 million in Q2 2023.
- Its 3-year average for Income from Continuing Operations is -$7.9 million, with a median of -$8.5 million in 2021.
- In the last 5 years, Candel Therapeutics' Income from Continuing Operations slumped by 197.01% in 2021 and then skyrocketed by 31.61% in 2023.
- Quarterly analysis of 4 years shows Candel Therapeutics' Income from Continuing Operations stood at -$6.1 million in 2020, then decreased by 27.57% to -$7.8 million in 2021, then fell by 1.60% to -$7.9 million in 2022, then soared by 31.61% to -$5.4 million in 2023.
- Its Income from Continuing Operations was -$5.4 million in Q4 2023, compared to -$9.0 million in Q3 2023 and -$9.8 million in Q2 2023.